نتایج جستجو برای: braf gene

تعداد نتایج: 1146646  

2013
Ehsan Nazemalhosseini Mojarad Roya Kishani Farahani Mahdi Montazer Haghighi Hamid Asadzadeh Aghdaei Peter JK Kuppen Mohammad Reza Zali

Knowledge about the clinical significance of V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutations in colorectal cancer (CRC) is growing. BRAF encodes a protein kinase involved with intracellular signaling and cell division. The gene product is a downstream effector of Kirsten Ras 1(KRAS) within the RAS/RAF/MAPK cellular signaling pathway. Evidence suggests that BRAF mutations, like K...

2017
Payal Jain Amanda Silva Harry J. Han Shih-Shan Lang Yuankun Zhu Katie Boucher Tiffany E. Smith Aesha Vakil Patrick Diviney Namrata Choudhari Pichai Raman Christine M. Busch Tim Delaney Xiaodong Yang Aleksandra K. Olow Sabine Mueller Daphne Haas-Kogan Elizabeth Fox Phillip B. Storm Adam C. Resnick Angela J. Waanders

Pediatric low-grade gliomas (PLGGs) are frequently associated with activating BRAF gene fusions, such as KIAA1549-BRAF, that aberrantly drive the mitogen activated protein kinase (MAPK) pathway. Although RAF inhibitors (RAFi) have been proven effective in BRAF-V600E mutant tumors, we have previously shown how the KIAA1549-BRAF fusion can be paradoxically activated by RAFi. While newer classes o...

2015
Eleonora Monti Michela Bovero Lorenzo Mortara Giorgia Pera Simonetta Zupo Elena Gugiatti Mariella Dono Barbara Massa Gian Luca Ansaldo Giusti Massimo

Background. Molecular diagnostics has offered new techniques for searching for mutations in thyroid indeterminate lesions. The study's aim was to evaluate the BRAF mutations' incidence in an Italian regional population. Subjects and Methods. 70 Caucasian patients born in Liguria with indeterminate or suspicious cytological diagnoses. Results. A BRAF gene mutation was successfully analyzed in 56...

Journal: :Journal of Investigative Dermatology 2022

Congenital melanocytic naevi (CMN) are moles present at birth, and when multiple or very extensive can involve other organ systems as well predisposing to melanoma. Some CMN develop a highly proliferative phenotype whose progression is poorly understood. Genotypically, caused by mosaic NRAS missense mutations in 67% of cases BRAF 7% cases. Single gene fusions have been previously described. To ...

2005
Norisato Mitsutake Jeffrey A. Knauf Shin Mitsutake Cleo Mesa Lei Zhang James A. Fagin

The activating mutation BRAF is the most prevalent genetic alteration in papillary thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this oncoprotein confers thyroid cancers with more aggressive properties. BRAF is also observed in thyroid micropapillary carcinomas and may thus be an early event in tumor development. To explore its biological consequences, we establ...

Journal: :The Journal of clinical investigation 2008
Stefan Pfister Wibke G Janzarik Marc Remke Aurélie Ernst Wiebke Werft Natalia Becker Grischa Toedt Andrea Wittmann Christian Kratz Heike Olbrich Rezvan Ahmadi Barbara Thieme Stefan Joos Bernhard Radlwimmer Andreas Kulozik Torsten Pietsch Christel Herold-Mende Astrid Gnekow Guido Reifenberger Andrey Korshunov Wolfram Scheurlen Heymut Omran Peter Lichter

The molecular pathogenesis of pediatric astrocytomas is still poorly understood. To further understand the genetic abnormalities associated with these tumors, we performed a genome-wide analysis of DNA copy number aberrations in pediatric low-grade astrocytomas by using array-based comparative genomic hybridization. Duplication of the BRAF protooncogene was the most frequent genomic aberration,...

Journal: :Oncology reports 2007
Naoto Yoshitake Shigehiko Fujii Kenichiroh Mukawa Keiichi Tominaga Hirokazu Fukui Kazuhito Ichikawa Shigeki Tomita Yuko Ono Yasuo Imai Akira Terano Hideyuki Hiraishi Takahiro Fujimori

Genetic alterations and their association with clinicopathological features in colorectal mucinous carcinoma (MC) remain unknown. In particular, little is known about the mutational status of the BRAF gene, which is activated by oncogenic Ras. This study aimed to evaluate the status of BRAF together with K-ras, p53 and mismatch-repair deficiency to clarify their association with tumorigenesis o...

2016
Emma R. Dorris Gordon Blackshields Gary Sommerville Mohsen Alhashemi Andrew Dias Victoria McEneaney Paul Smyth John J. O'Leary Orla Sheils

Oncogenic mutations in BRAF are common in melanoma and thyroid carcinoma and drive constitutive activation of the MAPK pathway. Molecularly targeted therapies of this pathway improves survival compared to chemotherapy; however, responses tend to be short-lived as resistance invariably occursCell line models of melanoma and thyroid carcinoma, +/- BRAF(V600E) activating mutation, were treated wit...

Journal: :Zhongguo fei ai za zhi = Chinese journal of lung cancer 2012
Zhimin Huang Yilong Wu

BRAF mutations have been found to be a driver mutation and maybe a therapy target in patients with non-small cell lung cancer. This article reviews the current understanding of BRAF gene, its structure, expression, the signal pathway, as well as its relationship with cancer especially the targeted therapies for non-small cell lung cancer.

2014
Brenda Hagen Van Anh Trinh

Somatic point mutations in the BRAF gene have been found in approximately 50% of melanomas. BRAF (V600E), the most common mutation, results in the constitutive activation of BRAF (V600E) kinase, sustaining MAPK signaling and perpetuating cell growth. This groundbreaking discovery led to the clinical development of vemurafenib, a selective BRAF inhibitor. Vemurafenib has been approved for the tr...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید